Lucie Ellis on Muck Rack

Lucie Ellis

Verified
United Kingdom
As seen in: Citeline, In Vivo, LinkedIn, Informa, Medtech Insight, Scrip, The Pink Sheet
Executive Editor @INVIVOnow lucie.ellis@informa.com All views are my own
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lucie

Contact Lucie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Lucie Ellis’s Biography

Read Full Bio →

Lucie joined the team in 2012 and is based in the UK. In her current role she covers news reporting, data visualisation projects for the Scrip website and handling of the weekly print issue. As a reporter Lucie covers a range of global news including: people and appointments; corporate financings and M&A activities; R&D news; and digital/social media development in the industry.

Articles

Deals Shaping Medtech And Diagnostics, September 2021

|
By Lucie Ellis Verified
| Medtech Insight Verified
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment - In Vitro Diagnostics, Medical Devices and Pharmaceuticals - and then categorized by type - Acquisition, Alliance, or Financing. This month's column covers deals announced in September 2021. Data provided by Biomedtracker. A selection of articles you might have missed from September 2021, including exclusive interviews and a look at pharma marketing trends in 2021.
Open in Who Shared Issue with article?

2020 Vision For Biopharma

|
By Lucie Ellis Verified
| pharmaintelligence.informa.com
ASK THE ANALYST Email Print Bookmark Welcome To The New Roaring Twenties 10 Dec 2019 Analysis Executive Summary Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020.
Open in Who Shared Issue with article?

Accessing CAR-T Therapies

|
By Lucie Ellis Verified, William Masters
| pharmaintelligence.informa.com
ASK THE ANALYST Email Print Bookmark 26 Nov 2019 Analysis Executive Summary Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients. Existing Subscriber? Sign in to continue reading. Need a specific report?
Open in Who Shared Issue with article?
See all 608 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified